Human Immunodeficiency Virus Clinical Trial
Official title:
Feasibility and Benefit of a Telerehabilitation Program in Human Immunodeficiency Virus-infected Patients
Verified date | October 2017 |
Source | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to assess the feasibility and the effects of a 6-week
telerehabilitation on the three domains of the International Classification of Functioning,
Disability and Health in HIV-infected patients under highly active antiretroviral therapy
(HAART).
HIV-infected patients were randomized either into an Endurance and Resistance Training
Exercise (ERTE) group or a control (CON) group. Telerehabilitation was realized in a public
fitness center, with online guidance and weekly telephone advice, 3 times per week for 6
weeks. Feasibility was determined by recruitment rate, retention rate and adverse events.
Secondary outcomes were impact on body composition, inflammation and coagulation (C-reactive
protein, D-dimer), physical fitness and quality of life (WHOQOL-HIV).
Status | Completed |
Enrollment | 25 |
Est. completion date | April 1, 2015 |
Est. primary completion date | April 1, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - 18 years or older - under HAART treatment - native French speaker Exclusion Criteria: - AIDS diagnosis - physical and/or psychiatric impairments that seriously impaired physical activity - pregnant - Unstable (defined by any modification of health outcomes during the last 6 months). |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment rate | Number of eligible participants who enrolled in the program out of the number were recruited | At study completion (after 6 weeks) | |
Primary | Retention rate | Percentage of patients lost to follow-up | At study completion (after 6 weeks) | |
Primary | Adverse events | Percentage of patients who experienced one or more adverse events | At study completion (after 6 weeks) | |
Secondary | Weight | Weight (kg) is measured by using a bioelectrical impedance analysis | Assessments at baseline and at 6 weeks | |
Secondary | Lean body mass | Lean body mass (kg) is measured by using a bioelectrical impedance analysis | Assessments at baseline and at 6 weeks | |
Secondary | Fat body mass | Lean body mass (kg) is measured by using a bioelectrical impedance analysis | Assessments at baseline and at 6 weeks | |
Secondary | C-reactive protein | C-reactive protein is measured by a blood test | Assessments at baseline and at 12 weeks | |
Secondary | D-dimer | D-dimer is measured by a blood test | Assessments at baseline and at 12 weeks | |
Secondary | CD4+ T cell counts | CD4+ T cell counts is measured by a blood test | Assessments at baseline and at 12 weeks | |
Secondary | Viral load | Viral load is measured by a blood test | Assessments at baseline and at 12 weeks | |
Secondary | Functional exercise capacity | Functional exercise capacity is measured by a 6-minute walk test | Assessments at baseline and at 6 weeks | |
Secondary | Flexibility | Flexibility is measured by Toe touch test and sit and reach test | Assessments at baseline and at 6 weeks | |
Secondary | Lower body muscular strength | Lower body muscular strength is measured by 30-s chair-stand test | Assessments at baseline and at 6 weeks | |
Secondary | Upper limb strength | Upper limb strength is measured by hand grip strength tool | Assessments at baseline and at 6 weeks | |
Secondary | Quality of life | Quality of life is measured by World Health Organization Quality of Life HIV Instrument | Assessments at baseline and at 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03516318 -
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
|
N/A | |
Completed |
NCT04653194 -
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
|
Phase 3 | |
Completed |
NCT01792570 -
DRV/r + RPV QD: Efficacy and Toxicity Reduction
|
Phase 3 | |
Active, not recruiting |
NCT04826562 -
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
|
Phase 4 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Completed |
NCT02812329 -
Intervention to Encourage HIV Testing and Counseling Among Adolescents
|
Phase 1 | |
Completed |
NCT02919306 -
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
|
Phase 1/Phase 2 | |
Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
Completed |
NCT01944371 -
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01778374 -
Mater-Bronx Rapid HIV Testing Project.
|
N/A | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT01076179 -
Kaletra in Combination With Antiretroviral Agents
|
N/A | |
Completed |
NCT01490346 -
Tissue Drug Levels of HIV Medications
|
N/A | |
Completed |
NCT01460433 -
Problems With Immune Recovery in the Gut Tissue
|
N/A | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Terminated |
NCT04240210 -
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
|
Phase 4 | |
Active, not recruiting |
NCT04704336 -
Integration of Hypertension Management Into HIV Care in Nigeria
|
N/A | |
Completed |
NCT03254277 -
3BNC117-LS First-in-Human Phase 1 Study
|
Phase 1 |